IMPE Abstracts

Background: Pediatric growth hormone deficiency (pGHD) is treated with daily somatropin (recombinant human growth hormone) injections. High discontinuation rates and poor adherence to treatment, which may be associated with worse growth outcomes, have been documented in Japan, EU and the US.Objectives: To describe adherence to daily somatropin treatment and assess the association between adherence and height velocity (HV...

Introduction: GH peak after GH stimulatory tests (GHST) diagnoses GH deficiency (GHD).Aims: To identify GH peak cutoff best discriminating GHD and non-GHD short stature (SS) patients.Methods: 901 children (0-18 yrs) were submitted to 1348 GHST between 2001 and 2016. We selected 458 patients suspected to have isolated SS (ISS= isolated GHD, familial SS, idiopathic SS) or GHD+ hypopi...

Introduction: Most children born Small for Gestational Age (SGA) show catch-up growth during the first 2 years of life. However, one part remains with short stature, changes in body composition (lower lean mass), and metabolic disorders. Recombinant Growth Hormone (rGH) is approved for the treatment of short stature in children born SGA. In addition to promoting catch-up growth, rGH acts on body composition and metabolic profile. Objective: This study assessed...

Introduction: Pediatric growth hormone deficiency (GHD) is characterized by short stature due to inadequate secretion of growth hormone (GH). Growth hormone stimulation test (GHST) can be used in diagnosing GHD. It is important to evaluate intracranial abnormality even though the incidence is not high. The study was aimed to find the incidence and predicting factors of pituitary abnormality in pediatric GHD in a single tertiary center.<s...